Press Room: Archives

< Back to Press Room

Duchesnay acquires the Canadian rights to Proctofoam-HC

Montreal, October 9, 2003 - Duchesnay, a pharmaceutical company located in the greater Montreal area, has recently acquired the prescription product Proctofoam-HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1% aerosol foam) for the Canadian market.
Proctofoam-HC is prescribed for the local treatment of anorectal disorders such as hemorrhoids, proctitis, cryptitis, fissures, postoperative pain and pruritus ani.

According to Duchesnay's Executive Vice-President Éric Gervais, "this unique metered-dose aerosol foam is particularly effective for the relief of postpartum hemorrhoids, and pain affecting as many as 3 out of 4 natural childbirthing women. At least 36 applications are contained in a single unit of Proctofoam-HC making it the most economic treatment available. Proctofoam-HC provides the ability to treat both internal and external hemorrhoids due to its dual applicator system. A simple topical application provides immediate relief of pain, inflammation and itching, without the risk of caine-like sensitization and without staining clothing".

Proctofoam-HC is listed as a benefit on the following provincial government formulary drug plans: British-Columbia, Alberta, New-Brunswick, Nova-Scotia and Newfoundland & Labrador and IFH. Also, most private insurance plans include Proctofoam-HC as a benefit.